Cargando…

Total, Free and Bioavailble 25 OH D and Bone Disease in Primary Hyperparathyroidism

Background: Low levels of vitamin D 25OHD are frequently described in PHP patients. The aim of this study was to evaluate bone parameters and vitamin D status in PHP patients and controls. Methods: Prior to surgery, 64 PHP patients and 63 healthy matched control subjects regarding age, gender and bo...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, Lívia Marcela, Ohe, Monique Nakayama, Pallone, Sthefanie Giovanna, Nacaguma, Isabela Ohki, Silva, Renata Elen Costa, Kunii, Ilda Sizue, Vieira, Jose Gilberto, Lazaretti-Castro, Marise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089935/
http://dx.doi.org/10.1210/jendso/bvab048.547
_version_ 1783687160224808960
author Santos, Lívia Marcela
Ohe, Monique Nakayama
Pallone, Sthefanie Giovanna
Nacaguma, Isabela Ohki
Silva, Renata Elen Costa
Kunii, Ilda Sizue
Vieira, Jose Gilberto
Lazaretti-Castro, Marise
author_facet Santos, Lívia Marcela
Ohe, Monique Nakayama
Pallone, Sthefanie Giovanna
Nacaguma, Isabela Ohki
Silva, Renata Elen Costa
Kunii, Ilda Sizue
Vieira, Jose Gilberto
Lazaretti-Castro, Marise
author_sort Santos, Lívia Marcela
collection PubMed
description Background: Low levels of vitamin D 25OHD are frequently described in PHP patients. The aim of this study was to evaluate bone parameters and vitamin D status in PHP patients and controls. Methods: Prior to surgery, 64 PHP patients and 63 healthy matched control subjects regarding age, gender and body mass index were enrolled in this study along 18 months. 25OHD and PTH were measured using Roche® Immunoassays. Bone mineral density (BMD) by dual X-ray absorptiometry (DXA) (Hologic QDR 4500) and TBS (InSight™) were determined in all patients and controls. Distribution of total, bioavailable and free (calculated) 25OH and its correlation with TBS and DXA in both groups was evaluated. DBP (vitamin D binding protein) SNPs genetic analysis was performed by ABI 7500 real time PCR System. None of the patients and controls were taking vitamin D supplements before the study. Results: PHP patients had lower BMD values than controls in all sites (p<0.01). TBS measurements were also reduced in PHP patients compared to controls, as expected (1233 vs 1280, p=0.04). There was no statistical difference in free, total and bioavailable 25OHD measurements between the PHP and the control group, mean±SD: 3.4±1.7 vs 3.1±1.7 pg/mL (p=0.44), 22.6± 6.1 vs 20.6± ng/dL (p=0.13) 1.53±0.66 vs 1.41±0.61 ng/mL (p=0.28), respectively. Likewise, there was no statistical difference in DBP haplotypes 1s/1s, 1f/1f, 1s/1f, 2/2, 1s/2, 1f/2 analysis between groups. There was no correlation with 25OHD and DXA measurements in both groups. However, total 25OHD presented statistical significant correlation with TBS measurements in the PHP group (r=0.28; p=0.02) and total, free and bioavailable 25OHD measurements with TBS in the control group (r=0.42; r=0.42; r=0.43; p<0.01). Conclusion: Vitamin D status correlates with TBS, but not with DXA, highlighting the relation of the vitamin D with the microarchitecture bone parameters in both PHP patients and controls. However, this correlation was more evident among controls than in PHP patients, spotlighting the primary hyperparathyroidism effects in bone.
format Online
Article
Text
id pubmed-8089935
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-80899352021-05-06 Total, Free and Bioavailble 25 OH D and Bone Disease in Primary Hyperparathyroidism Santos, Lívia Marcela Ohe, Monique Nakayama Pallone, Sthefanie Giovanna Nacaguma, Isabela Ohki Silva, Renata Elen Costa Kunii, Ilda Sizue Vieira, Jose Gilberto Lazaretti-Castro, Marise J Endocr Soc Bone and Mineral Metabolism Background: Low levels of vitamin D 25OHD are frequently described in PHP patients. The aim of this study was to evaluate bone parameters and vitamin D status in PHP patients and controls. Methods: Prior to surgery, 64 PHP patients and 63 healthy matched control subjects regarding age, gender and body mass index were enrolled in this study along 18 months. 25OHD and PTH were measured using Roche® Immunoassays. Bone mineral density (BMD) by dual X-ray absorptiometry (DXA) (Hologic QDR 4500) and TBS (InSight™) were determined in all patients and controls. Distribution of total, bioavailable and free (calculated) 25OH and its correlation with TBS and DXA in both groups was evaluated. DBP (vitamin D binding protein) SNPs genetic analysis was performed by ABI 7500 real time PCR System. None of the patients and controls were taking vitamin D supplements before the study. Results: PHP patients had lower BMD values than controls in all sites (p<0.01). TBS measurements were also reduced in PHP patients compared to controls, as expected (1233 vs 1280, p=0.04). There was no statistical difference in free, total and bioavailable 25OHD measurements between the PHP and the control group, mean±SD: 3.4±1.7 vs 3.1±1.7 pg/mL (p=0.44), 22.6± 6.1 vs 20.6± ng/dL (p=0.13) 1.53±0.66 vs 1.41±0.61 ng/mL (p=0.28), respectively. Likewise, there was no statistical difference in DBP haplotypes 1s/1s, 1f/1f, 1s/1f, 2/2, 1s/2, 1f/2 analysis between groups. There was no correlation with 25OHD and DXA measurements in both groups. However, total 25OHD presented statistical significant correlation with TBS measurements in the PHP group (r=0.28; p=0.02) and total, free and bioavailable 25OHD measurements with TBS in the control group (r=0.42; r=0.42; r=0.43; p<0.01). Conclusion: Vitamin D status correlates with TBS, but not with DXA, highlighting the relation of the vitamin D with the microarchitecture bone parameters in both PHP patients and controls. However, this correlation was more evident among controls than in PHP patients, spotlighting the primary hyperparathyroidism effects in bone. Oxford University Press 2021-05-03 /pmc/articles/PMC8089935/ http://dx.doi.org/10.1210/jendso/bvab048.547 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Bone and Mineral Metabolism
Santos, Lívia Marcela
Ohe, Monique Nakayama
Pallone, Sthefanie Giovanna
Nacaguma, Isabela Ohki
Silva, Renata Elen Costa
Kunii, Ilda Sizue
Vieira, Jose Gilberto
Lazaretti-Castro, Marise
Total, Free and Bioavailble 25 OH D and Bone Disease in Primary Hyperparathyroidism
title Total, Free and Bioavailble 25 OH D and Bone Disease in Primary Hyperparathyroidism
title_full Total, Free and Bioavailble 25 OH D and Bone Disease in Primary Hyperparathyroidism
title_fullStr Total, Free and Bioavailble 25 OH D and Bone Disease in Primary Hyperparathyroidism
title_full_unstemmed Total, Free and Bioavailble 25 OH D and Bone Disease in Primary Hyperparathyroidism
title_short Total, Free and Bioavailble 25 OH D and Bone Disease in Primary Hyperparathyroidism
title_sort total, free and bioavailble 25 oh d and bone disease in primary hyperparathyroidism
topic Bone and Mineral Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089935/
http://dx.doi.org/10.1210/jendso/bvab048.547
work_keys_str_mv AT santosliviamarcela totalfreeandbioavailble25ohdandbonediseaseinprimaryhyperparathyroidism
AT ohemoniquenakayama totalfreeandbioavailble25ohdandbonediseaseinprimaryhyperparathyroidism
AT pallonesthefaniegiovanna totalfreeandbioavailble25ohdandbonediseaseinprimaryhyperparathyroidism
AT nacagumaisabelaohki totalfreeandbioavailble25ohdandbonediseaseinprimaryhyperparathyroidism
AT silvarenataelencosta totalfreeandbioavailble25ohdandbonediseaseinprimaryhyperparathyroidism
AT kuniiildasizue totalfreeandbioavailble25ohdandbonediseaseinprimaryhyperparathyroidism
AT vieirajosegilberto totalfreeandbioavailble25ohdandbonediseaseinprimaryhyperparathyroidism
AT lazaretticastromarise totalfreeandbioavailble25ohdandbonediseaseinprimaryhyperparathyroidism